Table 4.
Laboratory test of 233 patients with COVID-19
| Blood routine (Unit, Normal range) | Total number N (%) | Stat | Total patient N = 233(%) |
Survival N = 205 (%) | Deceased N = 28 (%) |
|---|---|---|---|---|---|
| Leucocyte (×109/L, range 3.5–9.5) | 233 (100%) | Increased | 37 (15.9%) | 20 (9.8%) | 17 (60.7%) |
| Decreased | 27 (11.6%) | 25 (12.2%) | 2 (7.1%) | ||
| Normal | 169 (72.5%) | 160 (78%) | 9 (32.2%) | ||
| Neutrophil (×109/ L, range 1.8–6.3) | 233 (100%) | Increased | 58 (24.9%) | 36 (17.6%) | 22 (78.6%) |
| Decreased | 17 (7.3%) | 16 (7.8%) | 1 (3.6%) | ||
| Normal | 130 (67.8%) | 153 (74.6%) | 5 (17.8%) | ||
| Lymphocyte (×109/ L, range 1.1–3.2) | 233 (100%) | Decreased | 132 (57.6%) | 110 (53.7%) | 22 (78.6%) |
| Normal | 101 (42.2%) | 95 (46.3%) | 6 (21.4%) | ||
| Platelet (×109/ L, range 125–450) | 233 (100%) | Increased | 7 (3.1%) | 6 (2.9%) | 1 (3.6%) |
| Decreased | 29 (12.4%) | 23 (11.2%) | 6 (21.4%) | ||
| Normal | 197 (84.5%) | 176 (85.9%) | 21 (75%) | ||
| D-Dimer (mg/L; range < 0.55) | 34 (15%) | Increased | 19 (55.9%) | 12 (35.3%) | 7 (20.6%) |
| Normal | 15 (44.1%) | 15 (64.7%) | 0 | ||
| ALT (IU/L, range 0–64) | 202 (87%) | Increased | 22 (10.9%) | 19 (10.6%) | 3 (13.1%) |
| Normal | 180 (89.1%) | 160 (89.4%) | 20 (86.9%) | ||
| AST (IU/L, range 8–40) | 202 (87%) | Increased | 74 (36.6%) | 57 (31.8%) | 17 (73.9%) |
| Normal | 128 (63.4%) | 122 (68.2%) | 6 (26.1%) | ||
| ALK.P (IU/L, range 25–320) | 195 (84%) | Increased | 36 (18.5%) | 30 (17.2%) | 6 (28.6%) |
| Normal | 159 (81.5%) | 144 (82.8%) | 15 (71.4%) | ||
| Total Bilirubin (mg/dL, range 0.4–1.3) | 180 (77%) | Increased | 24 (13.3%) | 19 (11.8%) | 5 (26.3%) |
| Decreased | 8 (4.4%) | 8 (5.1%) | 0 | ||
| Normal | 148 (82.3%) | 134 (83.1%) | 14 (73.7%) | ||
| Direct Bilirubin (mg/dL, range 0.1–0.3) | 180 (77%) | Increased | 73 (40.6%) | 62 (38.5%) | 11 (57.9%) |
| Decreased | 36 (20%) | 33 (20.5%) | 3 (15.7%) | ||
| Normal | 71 (39.4%) | 66 (41%) | 5 (26.4%) | ||
| Bun (mg/dL, range 5–24) | 225 (97%) | Increased | 59 (26.2%) | 38 (19.1%) | 21 (80.8%) |
| Normal | 166 (73.8%) | 161 (80.9%) | 5 (19.2%) | ||
| Creatinine (mg/dL, range 0.5–1.4) | 223 (96%) | Increased | 58 (26%) | 40 (20.3%) | 18 (69.2%) |
| Normal | 165 (74%) | 157 (79.7%) | 8 (30.8%) | ||
| CPK (IU/L, range 12–160) | 183 (79%) | Increased | 68 (37.2%) | 57 (35%) | 11 (55%) |
| Normal | 115 (62.8%) | 106 (65%) | 9 (45%) | ||
| LDH (IU/L, range 140–280) | 173 (74%) | Increased | 168 (97.1%) | 151 (97.4%) | 17 (94%) |
| Normal | 5 (2.9%) | 4 (2.6%) | 1 (6%) | ||
| C-Reactive Protein (mg/L, 0.0–6.0) | 233 (100%) | Increased | 206 (88.4%) | 179 (87.3%) | 27 (96.4%) |
| Normal | 27 (11.6%) | 26 (12.7%) | 1 (3.6%) | ||
| ESR (mm/h, 2–22) | 162 (70%) | Increased | 139 (85.8%) | 124 (90.7%) | 15 (100%) |
| Normal | 23 (14.2%) | 23 (9.3%) | 0 | ||
| NA (mEq/L, 135–145) | 209 (90%) | Increased | 7 (3.4%) | 3 (1.6%) | 4 (16%) |
| Decreased | 96 (45.9%) | 85 (46.2%) | 11 (44%) | ||
| Normal | 106 (50.7%) | 96 (52.2%) | 10 (40%) | ||
| K (mEq/L, 3.5–5.5) | 208 (90%) | Increased | 3 (1.4%) | 0 | 3 (12%) |
| Decreased | 49 (23.6%) | 43 (23.5%) | 6 (24%) | ||
| Normal | 156 (75%) | 140 (76.5%) | 16 (64%) | ||
| NLR (index, < 5) | 233 (100%) | Increased | 95 (40.8%) | 69 (33.7%) | 26 (92.9%) |
| Normal | 138 (59.2%) | 136 (66.3%) | 2 (7.1%) | ||
| PLR (index, < 200) | 233 (100%) | Increased | 104 (44.6%) | 84 (40.9%) | 20 (71.4%) |
| Normal | 129 (55.4%) | 121 (59.1%) | 8 (28.6%) | ||
| SII (index, < 500) | 233 (100%) | Increased | 159 (68.2%) | 133 (64.9%) | 26 (92.9%) |
| Normal | 74 (31.8%) | 72 (35.1%) | 2 (7.1%) |